1 BTC
=
- USD
Apogee Therapeutics, Inc. Common Stock
As of June 1, 2026 at 24:05 UTC
Chart
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Market Statistics
Trading Metrics
How to Buy APGE
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy APGE
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesApogee Therapeutics CEO Michael Thomas Henderson sold 20,000 shares (~$1.5 million) on March 11, 2026, representing 1.71% of his holdings. The sale was executed under a Rule 10b5-1 plan, suggesting it reflects a pre-planned strategy rather than negative sentiment. Despite the insider sale, the company's stock has surged nearly 100% in the past year. The article emphasizes that investors should focus on Apogee's positive Phase 2 clinical data showing 85% patient response durability, upcoming Phase 3 trials, and a $350 million equity offering that strengthens its balance sheet for late-stage development.
Apogee Therapeutics priced an underwritten public offering of 5 million shares at $70 per share, raising approximately $350 million in gross proceeds. The offering is expected to close on March 26, 2026. The company is a clinical-stage biotech firm developing novel biologics for inflammatory and immunology markets, with its lead program Zumilokibart (APG777) in development for atopic dermatitis, asthma, and eosinophilic esophagitis.
Apogee Therapeutics announced it will report 52-week Phase 2 APEX trial data for zumilokibart (APG777) in atopic dermatitis patients on March 23, 2026, via conference call at 8:00 a.m. ET. The company is advancing novel biologics targeting inflammatory and immunology markets.
Great Point Partners increased its stake in Apogee Therapeutics (APGE) by 70,000 shares to 374,000 shares worth $28.23 million, making it the fund's largest holding at 9.15% of assets. APGE stock has doubled over the past year and is advancing monoclonal antibody therapies for inflammatory diseases with Phase 2 atopic dermatitis data expected in H1 2026.
Apogee Therapeutics reported positive interim Phase 1b results for zumilokibart (APG777), its anti-IL-13 antibody, in mild-to-moderate asthma patients, demonstrating rapid and durable suppression of FeNO biomarker through 16 weeks with a favorable safety profile. The company also highlighted multiple anticipated 2026 milestones including Phase 2 APEX data readouts in atopic dermatitis and potential Phase 3 initiation by late 2026, with a strong cash position of $913 million supporting operations into H2 2028.